Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NewAmsterdam Pharma (NAMS) Current Deferred Revenue (2022 - 2025)

NewAmsterdam Pharma (NAMS) has disclosed Current Deferred Revenue for 4 consecutive years, with $4.0 million as the latest value for Q4 2025.

  • Quarterly Current Deferred Revenue fell 33.64% to $4.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $4.0 million through Dec 2025, down 33.64% year-over-year, with the annual reading at $4.0 million for FY2025, 33.64% down from the prior year.
  • Current Deferred Revenue hit $4.0 million in Q4 2025 for NewAmsterdam Pharma, up from $3.0 million in the prior quarter.
  • In the past five years, Current Deferred Revenue ranged from a high of $18.7 million in Q4 2022 to a low of $3.0 million in Q1 2025.
  • Historically, Current Deferred Revenue has averaged $7.5 million across 4 years, with a median of $6.0 million in 2024.
  • Biggest YoY gain for Current Deferred Revenue was 33.64% in 2025; the steepest drop was 62.67% in 2025.
  • Year by year, Current Deferred Revenue stood at $18.7 million in 2022, then plummeted by 46.64% to $10.0 million in 2023, then crashed by 39.68% to $6.0 million in 2024, then tumbled by 33.64% to $4.0 million in 2025.
  • Business Quant data shows Current Deferred Revenue for NAMS at $4.0 million in Q4 2025, $3.0 million in Q1 2025, and $6.0 million in Q4 2024.